دورية أكاديمية
أعرض في EDS

Prescription psychostimulants for cocaine use disorder: A review from molecular basis to clinical approach.

التفاصيل البيبلوغرافية
العنوان: Prescription psychostimulants for cocaine use disorder: A review from molecular basis to clinical approach.
المؤلفون: Tardelli VS; Departamento de Psiquiatria, Universidade Federal de Sao Paulo (Unifesp), Sao Paulo, SP, Brazil.; Translational Addiction Research Laboratory, Center for Addiction and Mental Health, Toronto, ON, Canada., Berro LF; Department of Psychiatry and Human Behavior, University of Mississipi Medical Center, Jackson, MS, USA., Gerra G; Mental Health Department, Azienda Unitá Sanitaria Locale, Parma, Italy., Tadonio L; Mental Health Department, Azienda Unitá Sanitaria Locale, Parma, Italy., Bisaga A; The Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University and the New York State Psychiatric Institute, New York, NY, USA., Fidalgo TM; Departamento de Psiquiatria, Universidade Federal de Sao Paulo (Unifesp), Sao Paulo, SP, Brazil.; Young Leaders Program from the National Academy of Medicine, Brazil.
المصدر: Addiction biology [Addict Biol] 2023; Vol. 28 (4), pp. e13271.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Review
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 9604935 Publication Model: Print Cited Medium: Internet ISSN: 1369-1600 (Electronic) Linking ISSN: 13556215 NLM ISO Abbreviation: Addict Biol Subsets: MEDLINE
أسماء مطبوعة: Publication: Hoboken, NJ : Wiley-Blackwell
Original Publication: Abingdon, Oxfordshire, UK ; Cambridge, MA : Carfax, c1996-
مواضيع طبية MeSH: Cocaine-Related Disorders*/drug therapy , Cocaine-Related Disorders*/therapy , Central Nervous System Stimulants*/pharmacology , Central Nervous System Stimulants*/therapeutic use , Prescription Drugs*/pharmacology , Prescription Drugs*/therapeutic use, Humans ; Animals ; Evidence-Based Medicine ; Cognitive Behavioral Therapy
مستخلص: Cocaine use is a public health concern in many countries worldwide, particularly in the Americas and Oceania. Overdose deaths involving stimulants, such as cocaine, have been increasing markedly in North America, especially with concurrent opioid involvement. To date, no pharmacological treatment is available to treat stimulant (including cocaine) use disorders. Prescription psychostimulants (PPs) could be useful to treat cocaine use disorder (CUD) as they share the pharmacological effects with cocaine, as evidenced by a recent meta-analysis that assessed 38 randomized clinical trials (RCTs). PPs were found to promote sustained abstinence and reduce drug use in patients with CUD. The aim of this paper is to provide a narrative review of the clinical pharmacology of PPs and comment on the current stage of evidence supporting PPs to treat CUD. We also propose a model of care that integrates PPs with evidence-based psychosocial interventions (such as cognitive-behavioural therapy [CBT] and contingency management [CM]), a harm reduction approach and case management with social support.
(© 2023 Society for the Study of Addiction.)
References: Drug Alcohol Depend. 2019 Aug 1;201:227-235. (PMID: 31254749)
Neuropsychopharmacology. 2021 Jan;46(2):305-315. (PMID: 32682325)
Cochrane Database Syst Rev. 2016 Mar 19;3:CD006306. (PMID: 26992929)
J Dual Diagn. 2017 Jul-Sep;13(3):219-229. (PMID: 28414579)
Mol Neurobiol. 1995 Aug-Dec;11(1-3):1-19. (PMID: 8561954)
J Psychoactive Drugs. 2022 Jan-Mar;54(1):25-33. (PMID: 33749541)
Adv Pharmacol. 2014;69:129-76. (PMID: 24484977)
Future Med Chem. 2012 Feb;4(2):245-65. (PMID: 22300101)
Neuropsychopharmacology. 2018 Jul;43(8):1753-1762. (PMID: 29703999)
Biol Psychiatry. 2020 Jan 1;87(1):82-88. (PMID: 31420089)
Addiction. 2016 Aug;111(8):1337-46. (PMID: 26826006)
Am J Psychiatry. 2000 Jul;157(7):1134-40. (PMID: 10873923)
Addiction. 2020 Sep;115(9):1683-1694. (PMID: 32096302)
Addiction. 2014 Sep;109(9):1414-25. (PMID: 24995905)
J Subst Abuse Treat. 2021 Mar;122:108219. (PMID: 33353790)
J Gen Intern Med. 2019 Dec;34(12):2858-2873. (PMID: 31183685)
J Chem Neuroanat. 2000 Dec;20(3-4):271-80. (PMID: 11207425)
Lancet. 2016 May 28;387(10034):2226-34. (PMID: 27015909)
J Subst Abuse Treat. 2016 Sep;68:74-82. (PMID: 27431050)
Neuropsychopharmacology. 2015 Jul;40(8):1826-36. (PMID: 25689882)
Harm Reduct J. 2020 Jan 10;17(1):6. (PMID: 31924209)
J Pharmacol Exp Ther. 1994 Dec;271(3):1678-85. (PMID: 7996484)
JAMA Psychiatry. 2020 Nov 1;77(11):1105-1106. (PMID: 32667643)
Subst Abuse Treat Prev Policy. 2011 Feb 14;6:3. (PMID: 21320347)
Subst Abuse Treat Prev Policy. 2007 Mar 29;2:10. (PMID: 17394653)
Psychopharmacology (Berl). 2010 Jun;210(3):439-48. (PMID: 20386883)
CNS Drugs. 2020 Apr;34(4):337-365. (PMID: 32185696)
Am J Drug Alcohol Abuse. 1985;11(3-4):193-7. (PMID: 4091158)
PLoS One. 2020 Jun 18;15(6):e0234809. (PMID: 32555667)
Addiction. 2018 Jan;113(1):146-147. (PMID: 29226534)
Pharmacol Biochem Behav. 1990 Jan;35(1):237-44. (PMID: 2315363)
Drug Alcohol Depend. 2016 Nov 01;168:263-273. (PMID: 27736680)
Cochrane Database Syst Rev. 2016 Sep 27;9:CD007380. (PMID: 27670244)
Prog Mol Biol Transl Sci. 2011;98:1-46. (PMID: 21199769)
Drug Alcohol Depend. 2014 May 1;138:225-8. (PMID: 24629632)
J Neurosci. 2001 Apr 15;21(8):2799-807. (PMID: 11306632)
Cureus. 2018 Sep 18;10(9):e3328. (PMID: 30473961)
Acta Psychiatr Scand. 1990 Sep;82(3):223-7. (PMID: 2248048)
Drug Alcohol Depend. 1993 Jan;31(2):149-58. (PMID: 8436060)
Behav Res Ther. 2018 Dec;111:57-63. (PMID: 30316027)
Addiction. 2016 May;111(5):767-74. (PMID: 26503542)
J Phys Chem B. 2009 Nov 12;113(45):15057-66. (PMID: 19831380)
J Clin Psychopharmacol. 1997 Dec;17(6):485-8. (PMID: 9408812)
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD002209. (PMID: 19588333)
Drug Alcohol Depend. 2020 Jan 1;206:107700. (PMID: 31753736)
J Consult Clin Psychol. 2021 Jan;89(1):58-71. (PMID: 33507776)
JAMA Netw Open. 2021 May 3;4(5):e218049. (PMID: 33961037)
Eur Addict Res. 2011;17(2):80-9. (PMID: 21178355)
Clin Toxicol (Phila). 2015 Jun;53(5):477-85. (PMID: 25832473)
BMJ Open. 2021 May 18;11(5):e044696. (PMID: 34006547)
Addiction. 2017 Dec;112(12):2191-2201. (PMID: 28603836)
Neuropsychopharmacology. 2008 Jan;33(2):219-25. (PMID: 17443127)
JAMA. 2020 Jul 7;324(1):39-40. (PMID: 32459292)
Addict Behav. 2014 Jan;39(1):297-301. (PMID: 24455783)
Behav Processes. 2012 May;90(1):142-53. (PMID: 22421220)
J Pharmacol Exp Ther. 2002 Mar;300(3):831-7. (PMID: 11861788)
Psychopharmacology (Berl). 2020 Aug;237(8):2233-2255. (PMID: 32601988)
Int J Drug Policy. 2015 Apr;26(4):352-63. (PMID: 25662894)
Am J Drug Alcohol Abuse. 2021 May 4;47(3):402-409. (PMID: 33797985)
Clin Pharmacol Ther. 2011 Feb;89(2):276-82. (PMID: 21178989)
Trends Pharmacol Sci. 1992 May;13(5):193-200. (PMID: 1604712)
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Nov 15;31(8):1601-13. (PMID: 17888557)
JAMA Psychiatry. 2021 Dec 1;78(12):1329-1342. (PMID: 34550301)
PLoS Med. 2018 Dec 26;15(12):e1002715. (PMID: 30586362)
Addiction. 2014 Sep;109(9):1426-36. (PMID: 24750232)
J Pharmacol Exp Ther. 1995 Dec;275(3):1551-9. (PMID: 8531128)
Drug Alcohol Depend. 2015 Jul 1;152:62-7. (PMID: 25982007)
Ann N Y Acad Sci. 1992 Jun 28;654:171-91. (PMID: 1632582)
Biochem Pharmacol. 2008 Jan 1;75(1):196-217. (PMID: 17825265)
J Subst Abuse Treat. 1984;1(2):107-12. (PMID: 6536756)
Biochim Biophys Acta. 1993 Oct 4;1144(3):249-63. (PMID: 8104483)
Int J Drug Policy. 2015 Dec;26(12):1177-82. (PMID: 26500166)
Drug Alcohol Depend. 2016 Jan 1;158:1-7. (PMID: 26652899)
J Consult Clin Psychol. 2016 Oct;84(10):907-12. (PMID: 27454780)
J Neurosci. 2018 Jan 10;38(2):484-497. (PMID: 29175958)
Psychopharmacology (Berl). 2017 Sep;234(17):2607-2617. (PMID: 28584928)
Neuropharmacology. 2011 Jul-Aug;61(1-2):245-51. (PMID: 21521647)
Brain Res. 1993 Nov 19;628(1-2):17-25. (PMID: 8313144)
Addiction. 2010 Jan;105(1):146-54. (PMID: 19839966)
Psychopharmacology (Berl). 1997 May;131(1):40-8. (PMID: 9181634)
Eur J Pharmacol. 2000 Oct 6;406(1):1-13. (PMID: 11011026)
Ann Intern Med. 2017 Feb 21;166(4):268-278. (PMID: 27919103)
Forensic Sci Med Pathol. 2021 Jun;17(2):208-215. (PMID: 33237521)
Addiction. 2020 May;115(5):946-958. (PMID: 31912625)
Am J Psychiatry. 1983 Jun;140(6):784-5. (PMID: 6846640)
معلومات مُعتمدة: K99 DA049886 United States DA NIDA NIH HHS; R00 DA049886 United States DA NIDA NIH HHS
فهرسة مساهمة: Keywords: cocaine; cocaine use disorder; prescription amphetamines; stimulants, dopaminergic agonists
المشرفين على المادة: 0 (Central Nervous System Stimulants)
0 (Prescription Drugs)
تواريخ الأحداث: Date Created: 20230405 Date Completed: 20230421 Latest Revision: 20240102
رمز التحديث: 20240102
مُعرف محوري في PubMed: PMC10499006
DOI: 10.1111/adb.13271
PMID: 37016755
قاعدة البيانات: MEDLINE
الوصف
تدمد:1369-1600
DOI:10.1111/adb.13271